Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)

T. M. Reshetnyak; E. A. Aseeva; A. A. Shumilova; N.  Yu. Nikishina; S. I. Glukhova; S. Yu. Shkireeva; A. M. Lila

Modern Rheumatology Journal
Sovremennaâ revmatologiâ

ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)

User

eng | рус

Modern Rheumatology Journal

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Reshetnyak TM, Aseeva EA, Shumilova AA, Nikishina NY, Glukhova SI, Shkireeva SY, Lila AM. Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2024;18(2):16–24. (In Russ.) https://doi.org/10.14412/1996-7012-2024-2-16-24

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles

Editor-in-Chief

Al. M. Lila

Article Tools

Indexing metadata

How to cite item

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation

Tatiana Magomedalievna Reshetnyak